Pharming Group N.V. | Mid-cap | Healthcare
€1.26
0.80%
| Pharming Group N.V Stock Comparison:
Pharming Group N.V vs Galapagos NVPharming Group N.V vs VivoryonPharming Group N.V vs Koninklijke PhilipsPharming Group N.V vs AMG CriticalPharming Group N.V vs Wereldhave N.VPharming Group N.V vs AEX Index | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 79.4M
Gross Profit 71.7M 90.38%
Operating Income 7.7M 9.65%
Net Income 3.9M 4.88%

Balance Sheet Metrics

Total Assets 380.3M
Total Liabilities 176.2M
Shareholders Equity 204.1M
Debt to Equity 0.86

Cash Flow Metrics

Operating Cash Flow 10.2M
Free Cash Flow 9.9M

Revenue & Profitability Trend

Pharming Group N.V Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i253.0M245.3M205.6M204.2M217.9M
Cost of Goods Sold i30.1M25.2M17.6M21.7M24.2M
Gross Profit i222.9M220.1M188.1M182.5M193.7M
Gross Margin % i88.1%89.7%91.5%89.4%88.9%
Operating Expenses
Research & Development i70.8M68.9M52.5M72.3M39.6M
Selling, General & Administrative i84.5M87.5M68.9M49.4M66.7M
Other Operating Expenses i62.8M76.8M49.7M35.3M7.9M
Total Operating Expenses i218.0M233.2M171.0M156.9M114.2M
Operating Income i-3.1M-22.3M9.9M19.5M78.3M
Operating Margin % i-1.2%-9.1%4.8%9.6%35.9%
Non-Operating Items
Interest Income i4.1M3.7M85.0K54.4K734.2K
Interest Expense i7.4M6.0M5.4M6.3M6.1M
Other Non-Operating Income220.5K12.7M10.5M10.5M-27.6M
Pre-tax Income i-7.2M-12.0M15.0M23.7M45.3M
Income Tax i2.9M-1.5M1.3M7.3M6.5M
Effective Tax Rate % i0.0%0.0%8.8%30.7%14.4%
Net Income i-10.1M-10.5M13.7M16.4M38.8M
Net Margin % i-4.0%-4.3%6.7%8.0%17.8%
Key Metrics
EBITDA i12.2M-2.8M22.5M40.3M87.9M
EPS (Basic) i€-0.02€-0.02€0.02€0.02€0.06
EPS (Diluted) i€-0.02€-0.02€0.02€0.02€0.06
Basic Shares Outstanding i585550363720495930668585671659491263653313301
Diluted Shares Outstanding i585550363720495930668585671659491263653313301

Income Statement Trend

Pharming Group N.V Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i46.8M61.7M207.3M197.1M210.7M
Short-term Investments i96.3M151.7M0--
Accounts Receivable i35.4M35.4M21.0M18.6M24.1M
Inventory i47.5M56.8M42.3M28.0M21.7M
Other Current Assets-----
Total Current Assets i237.3M316.3M277.5M256.1M270.3M
Non-Current Assets
Property, Plant & Equipment i4.6M5.1M4.7M19.5M16.6M
Goodwill i52.0M71.3M75.1M86.1M96.6M
Intangible Assets i52.0M71.3M75.1M86.1M96.6M
Long-term Investments-----
Other Non-Current Assets27.3M31.3M24.1M22.6M33.3M
Total Non-Current Assets i103.6M146.5M148.3M151.8M159.4M
Total Assets i340.9M462.9M425.8M408.0M429.7M
Liabilities
Current Liabilities
Accounts Payable i8.6M16.0M8.8M7.8M13.8M
Short-term Debt i6.1M5.4M5.2M4.4M4.1M
Current Portion of Long-term Debt-----
Other Current Liabilities----25.9M
Total Current Liabilities i62.9M78.0M59.7M48.0M78.9M
Non-Current Liabilities
Long-term Debt i89.6M166.1M161.5M161.7M162.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities---169.4K217.7K
Total Non-Current Liabilities i89.6M166.1M161.5M161.9M162.4M
Total Liabilities i152.5M244.1M221.2M209.9M241.3M
Equity
Common Stock i6.6M7.7M7.5M7.6M7.5M
Retained Earnings i-234.8M-265.3M-256.4M-280.5M-303.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i188.4M218.8M204.6M198.1M188.3M
Key Metrics
Total Debt i95.7M171.5M166.7M166.1M166.3M
Working Capital i174.4M238.4M217.8M208.1M191.4M

Balance Sheet Composition

Pharming Group N.V Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-7.2M-12.0M15.0M23.7M45.3M
Depreciation & Amortization i13.7M15.9M13.2M20.1M8.5M
Stock-Based Compensation i9.6M9.3M6.4M9.3M6.7M
Working Capital Changes i-6.2M-33.2M-12.4M238.2K-11.2M
Operating Cash Flow i8.2M-15.7M21.6M45.0M81.1M
Investing Activities
Capital Expenditures i-----
Acquisitions i007.3M0-337.8K
Investment Purchases i-242.3M-382.0M0-4.7M0
Investment Sales i269.9M232.8M00-
Investing Cash Flow i27.6M-127.9M7.3M-4.7M-337.8K
Financing Activities
Share Repurchases i-----
Dividends Paid i00000
Debt Issuance i89.1M-00146.7M
Debt Repayment i-118.4M-5.1M-3.3M-3.3M-61.0M
Financing Cash Flow i-29.3M-5.1M-1.0M-24.1M64.5M
Free Cash Flow i-2.2M-18.8M20.5M21.7M70.2M
Net Change in Cash i6.5M-148.7M27.9M16.1M145.3M

Cash Flow Trend

Pharming Group N.V Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 57.15
Forward P/E -120.60
Price to Book 3.45
Price to Sales 2.46
PEG Ratio -120.60

Profitability Ratios

Profit Margin -2.41%
Operating Margin 3.27%
Return on Equity -3.70%
Return on Assets 2.85%

Financial Health

Current Ratio 2.80
Debt to Equity 53.57
Beta 0.59

Per Share Data

EPS (TTM) €-0.01
Book Value per Share €0.35
Revenue per Share €0.50

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
pharm841.3M57.153.45-3.70%-2.41%53.57
Galapagos NV 1.9B51.710.72-10.39%-103.14%0.32
Vivoryon 43.5M-2.0713.87-145.47%0.00%2.26
Koninklijke Philips 22.7B150.002.201.51%0.91%80.96
AMG Critical 914.5M99.331.492.93%0.68%137.63
Wereldhave N.V 844.8M9.450.827.92%43.56%84.90

Financial data is updated regularly. All figures are in the company's reporting currency.